Adalimumab for treating moderate to severe hidradenitis suppurativa

  • Technology appraisal guidance
  • TA392
  • Published: 

History

Documents created during the development process.

Expected publication

Final appraisal determination

Draft guidance: 1

Draft scope documents

Equality impact assessment- scoping

Draft scope for consultation (pre-referral) - January 2015

Provisional matrix (pre-referral) - January 2015